Resource overview
Chimeric antigen receptor T cell (CAR-T) therapies have changed the treatment landscape for several hematological malignancies. Yet manufacturing remains a major barrier to broader clinical impact. Workflows are often slow and costly.
A collaboration between University College London (UCL) and Sartorius has addressed these challenges, through a series of studies on stirred-tank bioreactor (STR)-based CAR-T manufacturing. The reviewed studies revealed that CAR-T cells can be expanded reliably in STRs without loss of quality or function.
It was demonstrated how the process may be optimized to produce more cells, faster, whilst maintaining the clinically viable phenotype. By combining STR bioprocessing with live-cell functional analysis and high-throughput screening (HTS) by cytometry, product function and phenotype may be ascertained.
Thus by incorporating cell characterization into STR bioprocessing, speedier batch release decisions occurred.
Key takeaways:
- Establishing the Baseline: Seed Train and Activation Parameters Set the Quality Ceiling
- Intensifying Expansion Without Sacrificing Function
- Serum-Free and Adaptive: Building a Clinically Transferable Process
- From Bench to Batch: Scale-Up With Functional Continuity
Resource details:
- Document type: eBook
- Page count: 14
- Read time: 8 minutes